36,100 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Strs Ohio

Strs Ohio acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 36,100 shares of the company’s stock, valued at approximately $566,000. Strs Ohio owned about 0.06% of Monte Rosa Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GLUE. AQR Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Monte Rosa Therapeutics in the third quarter worth $5,928,000. Marshall Wace LLP grew its stake in shares of Monte Rosa Therapeutics by 102.4% in the third quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock worth $6,690,000 after purchasing an additional 456,754 shares during the last quarter. Millennium Management LLC grew its stake in shares of Monte Rosa Therapeutics by 588.4% in the third quarter. Millennium Management LLC now owns 444,939 shares of the company’s stock worth $3,297,000 after purchasing an additional 380,308 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Monte Rosa Therapeutics by 301.4% in the second quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock worth $1,818,000 after purchasing an additional 302,639 shares during the last quarter. Institutional investors own 79.96% of the company’s stock.

Insider Activity

In other news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer owned 613,471 shares in the company, valued at approximately $10,993,400.32. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $18.10, for a total transaction of $455,468.40. Following the transaction, the insider owned 22,693 shares in the company, valued at $410,743.30. This represents a 52.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 37,150 shares of company stock worth $668,694. Company insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on GLUE. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Guggenheim dropped their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Piper Sandler restated an “overweight” rating and issued a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Wells Fargo & Company dropped their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Finally, Zacks Research lowered shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.80.

Monte Rosa Therapeutics Stock Down 2.1%

GLUE stock opened at $19.39 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics, Inc. has a 12-month low of $3.51 and a 12-month high of $25.77. The company’s fifty day simple moving average is $17.69 and its 200 day simple moving average is $17.40.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 52.22%. The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.13 earnings per share for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.